Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 19
Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Response to Letter]
Received 5 July 2023
Accepted for publication 11 July 2023
Published 17 July 2023 Volume 2023:19 Pages 1623—1624
Cheng-Chuan Chen, Xiao-Bin Wang
Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China
Correspondence: Xiao-Bin Wang, Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China, Tel +86 13708280087, Fax +86 830-3161222, Email [email protected]
View the original paper by Mr Chen and colleagues
This is in response to the Letter to the Editor
Dear editor
Thank you very much for your attention and advice, as this is indeed a thought-provoking issue. Although the US Food and Drug Administration (FDA) has not yet recognized the advantages of ketamine in treating depression and preventing suicide, relevant research results show that ketamine also has a significant role in preventing suicide.1 In addition, the results of a randomized controlled trial also showed that in the treatment of depression, both ketamine and esketamine have therapeutic effects.2
However, as you rightly pointed out, the adverse reactions related to ketamine have limited its widespread use in clinical applications, which may be the main reason why it has not been approved by the FDA. In contrast, as the only drug approved by the FDA, esketamine has better efficacy and safety. Therefore, we suggest considering the use of esketamine in future antidepressant or antisuicide intervention studies. If ketamine is used consistently, more careful consideration and strict ethical review are required.
We once again appreciate your interest in our research and value your valuable feedback.
Disclosure
The authors report no conflicts of interest in this communication.
References
1. Abbar M, Demattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 2022;376:e067194. doi:10.1136/bmj-2021-067194
2. Correia-Melo FS, Leal GC, Vieira F, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527–534. doi:10.1016/j.jad.2019.11.086
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.